secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0000950170-23-068816
Event type: earnings
Sentiment:  positive
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista hits Phase 3 attack target for sebetralstat; NDA on track for H1 2024
------------------------------------------------------------------------------

- Phase 3 KONFIDENT trial achieved targeted number of attacks; data readout early 2024, NDA filing expected H1 2024.
- Received Orphan Drug Status from Switzerland for sebetralstat, providing 15-year market protection.
- Net loss of $27.7M ($0.80/share) for Q2 FY24 vs. $22.3M ($0.90/share) year ago; revenue nil.
- Cash, equivalents and marketable securities $103.2M at Oct 31, 2023, down from $149.4M at Apr 30, 2023.
- R&D expenses $19.1M; G&A expenses $10.7M, both up YoY due to trial costs and commercial build-out.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023068816/0000950170-23-068816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023068816/kalv-20231207.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-068816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer